These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38160154)

  • 1. Completion of adjuvant S-1 chemotherapy after surgical resection for biliary tract cancer: A single center experience.
    Iwaki K; Yoh T; Nishino H; Nishio T; Koyama Y; Ogiso S; Ishii T; Kanai M; Hatano E
    Asian J Surg; 2024 Mar; 47(3):1383-1388. PubMed ID: 38160154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of S-1 Adjuvant Chemotherapy for Resected Biliary Tract Cancer: A Retrospective Propensity-Matched Analysis.
    Yoshida M; Yanagimoto H; Tsugawa D; Akita M; Urade T; Nanno Y; Fukushima K; Gon H; Komatsu S; Asari S; Kido M; Toyama H; Ajiki T; Fukumoto T
    Am Surg; 2024 Jun; 90(6):1279-1289. PubMed ID: 38226586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection.
    Kim YS; Jeong CY; Song HN; Kim TH; Kim HJ; Lee YJ; Hong SC
    Chin J Cancer; 2017 Jan; 36(1):9. PubMed ID: 28086990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
    Hosoda K; Fukushima K; Shimizu A; Motoyama H; Kubota K; Notake T; Sugenoya S; Hayashi H; Yasukawa K; Kobayashi R; Soejima Y
    Oncology; 2021; 99(11):703-712. PubMed ID: 34515195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer.
    Kim H; Heo MH; Kim JY
    BMC Gastroenterol; 2020 Jan; 20(1):20. PubMed ID: 31992208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
    Nakachi K; Konishi M; Ikeda M; Shimada K; Okusaka T; Saiura A; Ishii H; Sugiyama M; Furuse J; Sakamoto H; Shimamura T; Ohta T
    Int J Clin Oncol; 2018 Oct; 23(5):894-899. PubMed ID: 29705976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202.
    Kobayashi S; Nakachi K; Ikeda M; Konishi M; Ogawa G; Sugiura T; Yanagimoto H; Morinaga S; Wada H; Shimada K; Takahashi Y; Nakagohri T; Kamata K; Shimizu Y; Ajiki T; Hirano S; Gotohda N; Ueno M; Okusaka T; Furuse J
    Eur J Surg Oncol; 2024 Feb; 50(2):107324. PubMed ID: 38157649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer.
    Kainuma O; Miura F; Furukawa D; Yamamoto H; Cho A; Sano K; Nakagohri T; Asano T
    J Hepatobiliary Pancreat Sci; 2015 Nov; 22(11):789-94. PubMed ID: 26234468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.
    Harada N; Shirabe K; Yoshizumi T; Ikegami T; Uchiyama H; Soejima Y; Yamashita Y; Saeki H; Oki E; Kawanaka H; Morita M; Ikeda T; Matsuura H; Okadome K; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Dec; 104(12):539-48. PubMed ID: 24693682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of omega-3 fatty acid administration on completion rate of adjuvant chemotherapy for biliary tract cancer: study protocol for a single-centre, open-label, single-arm, historically controlled study.
    Ueno K; Ajiki T; Tsugawa D; Akita M; Hashimoto Y; Awazu M; Mukubo H; Komatsu S; Kuramitsu K; Terai S; Tanaka M; Toyama H; Kido M; Fukumoto T
    BMJ Open; 2019 Aug; 9(8):e029915. PubMed ID: 31401605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma.
    Motoyama H; Kobayashi A; Yokoyama T; Shimizu A; Kitagawa N; Notake T; Fukushima K; Masuo H; Yoshizawa T; Miyagawa SI
    World J Surg; 2017 Nov; 41(11):2817-2829. PubMed ID: 28717913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 Trial of Adjuvant Chemotherapy With S - 1 for Node-Positive Biliary Tract Cancer (N-SOG 09).
    Seita K; Ebata T; Mizuno T; Maeda A; Yamaguchi R; Kurumiya Y; Sakamoto E; Hiramatsu K; Ando M; Nagino M
    Ann Surg Oncol; 2020 Jul; 27(7):2348-2356. PubMed ID: 32180066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difficulty of adjuvant chemotherapy administration in patients with biliary tract cancer.
    Sumiyoshi T; Uemura K; Shintakuya R; Okada K; Baba K; Harada T; Serikawa M; Ishii Y; Nakamura S; Arihiro K; Murakami Y; Takahashi S
    Langenbecks Arch Surg; 2023 Nov; 408(1):445. PubMed ID: 37999810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Feasibility of Adjuvant Gemcitabine Plus Cisplatin Chemotherapy After Major Hepatectomy for Biliary Tract Cancer.
    Mori S; Aoki T; Shiraki T; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Sakuraoka Y; Iso Y; Kubota K
    Anticancer Res; 2021 Oct; 41(10):5231-5240. PubMed ID: 34593476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current status of adjuvant therapy for biliary tract cancer].
    Kato A; Miyazaki M
    Nihon Geka Gakkai Zasshi; 2014 Jul; 115(4):206-11. PubMed ID: 25154240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer.
    Yamanaka K; Hatano E; Kanai M; Tanaka S; Yamamoto K; Narita M; Nagata H; Ishii T; Machimoto T; Taura K; Uemoto S
    Int J Clin Oncol; 2014; 19(3):485-9. PubMed ID: 23765238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakamura H; Nakashima A; Sueda T
    Ann Surg; 2009 Dec; 250(6):950-6. PubMed ID: 19953713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
    Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
    BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
    Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).
    Itano O; Takemura Y; Kishida N; Tamagawa E; Shinozaki H; Ikeda K; Urakami H; Ei S; Hayatsu S; Suzuki K; Sakuragawa T; Ishii M; Shito M; Aiura K; Fujisaki H; Takano K; Matsui J; Minagawa T; Shinoda M; Kitago M; Abe Y; Yagi H; Oshima G; Hori S; Kitagawa Y
    BMC Cancer; 2020 Jul; 20(1):688. PubMed ID: 32703191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.